Akebia Therapeutics Inc (NASDAQ:AKBA) – Research analysts at Piper Jaffray Companies lowered their Q1 2019 earnings estimates for shares of Akebia Therapeutics in a report released on Monday, March 18th. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter, down from their previous forecast of ($0.24). Piper Jaffray Companies also issued estimates for Akebia Therapeutics’ Q2 2019 earnings at ($0.35) EPS, Q3 2019 earnings at ($0.36) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.35) EPS, FY2020 earnings at ($0.50) EPS, FY2021 earnings at $0.50 EPS, FY2022 earnings at $1.99 EPS and FY2023 earnings at $2.80 EPS.

AKBA has been the topic of several other research reports. ValuEngine cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 22nd. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Tuesday, January 15th. BidaskClub upgraded shares of Akebia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 7th. Finally, Mizuho restated a “buy” rating and issued a $17.00 target price on shares of Akebia Therapeutics in a report on Tuesday, December 4th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $14.28.

Shares of Akebia Therapeutics stock opened at $8.62 on Thursday. Akebia Therapeutics has a 52-week low of $5.20 and a 52-week high of $12.31. The company has a market capitalization of $462.18 million, a PE ratio of -4.87 and a beta of 1.46.

A number of hedge funds have recently made changes to their positions in AKBA. Russell Investments Group Ltd. lifted its stake in Akebia Therapeutics by 29.1% in the third quarter. Russell Investments Group Ltd. now owns 30,432 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 6,860 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Akebia Therapeutics in the third quarter valued at $703,000. Candriam Luxembourg S.C.A. acquired a new stake in Akebia Therapeutics in the third quarter valued at $618,000. BlackRock Inc. lifted its stake in Akebia Therapeutics by 5.1% in the third quarter. BlackRock Inc. now owns 5,268,846 shares of the biopharmaceutical company’s stock valued at $46,523,000 after acquiring an additional 253,811 shares during the last quarter. Finally, Abrams Capital Management L.P. acquired a new stake in Akebia Therapeutics in the third quarter valued at $9,883,000.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.

See Also: How Investors Use a Balance Sheet

Earnings History and Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.